Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Abbott wins U.S. approval for body-absorbable stent

U.S. health regulators said they approved a stent by Abbott Laboratories that is the first designed to be absorbed into the bloodstream after it is implanted.

Read More »

XBiotech’s Colorectal Cancer Drug Claims Fall Apart, Shares Plummet

XBiotech said its experimental colorectal cancer drug Xilonix demonstrated an increase in overall survivability among patients, however those figures appear to fall apart under close scrutiny, which drove the company’s shares down more than 46 percent.

Read More »

Roche to Slash Approximately 350 IT Jobs by End of 2017

Swiss drugmaker Roche will terminate approximately 350 information technology (IT) employees across the globe by the end of 2017.

Read More »

BIND Therapeutics Accepts Pfizer’s ‘Stalking Horse’ Asset Bid

Two months after filing for 11 bankruptcy, Bind Therapeutics accepted a “stalking horse” bid from Pfizer.

Read More »

Bristol-Myers Scoops Up Swedish Firm

New York-based Bristol-Myers Squibb acquired Stockholm, Sweden-based Cormorant Pharmaceuticals in a deal that could hit $520 million.

Read More »

Takeda and TiGenix Enter into Licensing Agreement for Ex-U.S. Rights to Cx601 for the Treatment of Complex Perianal Fistulas in Patients with Crohn’s Disease

Takeda Pharmaceutical Company Limited and TiGenix NV announced that the companies have entered into an exclusive ex-U.S. license, development and commercialization agreement for Cx601, a suspension of allogeneic adipose-derived stem cells (eASC) injected intra-lesionally for the treatment of complex perianal fistulas in patients with Crohn’s disease.

Read More »

Hundreds of companies sell unapproved stem cell therapies in U.S

More than 300 companies are marketing unapproved stem cell procedures at more than 500 clinics in the U.S.

Read More »

Top Spanish drugmaker fears disruption if EMA moves

The likely relocation of the EMA from London threatens to disrupt the approval of new drugs and is a medium and long-term worry for top Spanish drugmaker Almirall, its chief executive said.

Read More »

Spain’s Almirall eyes Valeant skin drugs

Spanish drugmaker Almirall, which is building up its business in skin treatments, could be interested in acquiring dermatology assets from Canada’s Valeant Pharmaceuticals.

Read More »

Obama says Congress must end deadlock on Zika funding

U.S. President Barack Obama said Congress must end its deadlock on funding to combat the Zika virus before lawmakers head out to recess later this summer.

Read More »

UK drugs regulator halts approvals for Indian clinical trials firm

The UK’s healthcare regulator has suspended marketing approval for a widely used antibiotic that had won clearance based on clinical trials conducted by India’s Quest Life Sciences, due to concerns over the integrity of trial data.

Read More »

Tesaro Stock Soars as Acquisition Rumors Swirl after Excellent Phase III Results

Tesaro stock took a massive jump this week, rocketing from $37.21 on June 28 to a share price of $81.19. The rise is likely the results of a June 29 announcement that its Phase III clinical trial of niraparib met its endpoints of progression-free survival (PFS) in patients with ovarian cancer. Niraparib is an oral, once-daily PARP inhibitor in three clinical trials.

Read More »

KaloBios Emerges from Chapter 11 Bankruptcy

KaloBios Pharmaceuticals has emerged from Chapter 11 bankruptcy and acquired the rights from Savant Neglected Diseases to develop benznidazole for treating Chagas disease.

Read More »

AstraZeneca PLC, Valeant and LEO Pharma Shuffle Dermatology Rights, Potential $1 Billion in Sales at Stake

Valeant Pharmaceuticals International, headquartered in Laval, Quebec, announced today that the company and UK-based AstraZeneca had amended Valeant’s license for brodalumab. The IL-17 receptor monoclonal antibody brodalumab is being evaluated in Europe in patients with moderate-to-severe plaque psoriasis.

Read More »

Arena Cutting 73 Percent of Jobs

San Diego-based Arena Pharmaceuticals announced that it is laying off about 100 people as part of a strategic change in priorities.

Read More »

Health officials race to prevent Congo yellow fever disaster

It is the stuff of a disaster movie: an outbreak of yellow fever in Congo’s capital city, full of unvaccinated people mostly huddled together in slums with too few drains and the kind of sticky, fetid climate that mosquitoes love.

Read More »

AstraZeneca sells two dermatology drug rights

British drugmaker AstraZeneca Plc said it sold the rights to develop an experimental mid-stage drug to treat atopic dermatitis to privately-held LEO Pharma.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom